首页> 外文期刊>癌症生物学与医学:英文版 >Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells
【24h】

Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells

机译:局灶性粘附激酶的抑制增强了通过CD8 + T细胞在胰腺癌中的抗肿瘤响应

获取原文
获取原文并翻译 | 示例
       

摘要

Objective:Pancreatic ductal adenocarcinoma(PDAC)is a deadly malignancy,due in large part to its resistance to conventional therapies,including radiotherapy(RT).Despite RT exerting a modest antitumor response,it has also been shown to promote an immunosuppressive tumor microenvironment.Previous studies demonstrated that focal adhesion kinase inhibitors(FAKi)in clinical development inhibit the infiltration of suppressive myeloid cells and T regulatory(T regs)cells,and subsequently enhance effector T cell infiltration.FAK inhibitors in clinical development have not been investigated in combination with RT in preclinical murine models or clinical studies.Thus,we investigated the impact of FAK inhibition on RT,its potential as an RT sensitizer and immunomodulator in a murine model of PDAC.Methods:We used a syngeneic orthotopic murine model to study the effect of FAKi on hypofractionated RT.Results:In this study we showed that IN10018,a small molecular FAKi,enhanced antitumor response to RT.Antitumor activity of the combination of FAKi and RT is T cell dependent.FAKi in combination with RT enhanced CD8+T cell infiltration significantly in comparison to the radiation or FAKi treatment alone(P<0.05).FAKi in combination with radiation inhibited the infiltration of granulocytes but enhanced the infiltration of macrophages and T regs in comparison with the radiation or FAKi treatment alone(P<0.01).Conclusions:These results support the clinical development of FAKi as a radiosensitizer for PDAC and combining FAKi with RT to prime the tumor microenvironment of PDAC for immunotherapy.
机译:目的:胰腺导管腺癌(PDAC)是一种致命的恶性肿瘤,其巨大的抵抗常规疗法的抵抗力,包括放射疗法(RT)。施加适度的抗肿瘤反应,还显示出促进免疫抑制肿瘤微环境。以前的研究表明,临床发育中的局灶性粘附激酶抑制剂(FAKI)抑制抑制骨髓细胞和T调节(T regs)细胞的渗透,随后增强效应T细胞浸润。临床开发中的抑制剂尚未与之调查RT在临床前小鼠模型或临床研究中。从PDAC.Methods的小鼠模型中调查了对RT的影响,其作为RT敏化剂和免疫调节剂的潜力:我们使用了一款同工原位小鼠模型来研究效果FAKI在次规的RT.RESULTS:在这项研究中,我们表明,IN10018,小分子FAKI,增强抗肿瘤反应RT。 FAKI和RT组合的抗肿瘤活性是T细胞依赖性。与RT增强的CD8 + T细胞浸润组合,与单独的辐射或FAKI处理相比,与辐射相结合的辐射或FAKI治疗抑制浸润与单独的辐射或FAKI治疗相比,粒细胞,但增强了巨噬细胞和T regs的渗透(P <0.01)。这些结果支持FAKI作为PDAC的辐射敏化剂的临床开发,并将FAKI与RT与RT的充气剂浸入肿瘤微环境PDAC用于免疫疗法。

著录项

  • 来源
    《癌症生物学与医学:英文版》 |2021年第001期|P.206-214|共9页
  • 作者单位

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Surgery Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Surgery Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    Inx Med Shanghai Shanghai 201202 China;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Surgery Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Surgery Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Surgery Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Surgery Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

    The Sydney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore 21287 MD USAThe Pancreatic Cancer Precision Medicine Center of Excellence Program Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Oncology Johns Hopkins University School of Medicine Baltimore 21287 MD USADepartment of Surgery Johns Hopkins University School of Medicine Baltimore 21287 MD USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 肿瘤学;
  • 关键词

    Focal adhesion protein-tyrosine kinases; radiotherapy; pancreatic neoplasms; immunomodulation;

    机译:局灶性粘附蛋白 - 酪氨酸激酶;放射疗法;胰腺肿瘤;免疫调节;
  • 入库时间 2022-08-19 04:57:03
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号